Thomas Striepe - Sangui Biotech President, CEO

All Insiders Germany . 
Stock . Sangui Biotech International . Stakeholders . Insider . Thomas_Striepe
SBH Stock  EUR 0  0.00  0.00%   

Insider

Thomas Striepe is President, CEO of Sangui Biotech International
Age 61
Phone49 40 609 3120
Webhttps://www.sanguibiotech.com

Sangui Biotech Management Efficiency

The company has return on total asset (ROA) of (0.6411) % which means that it has lost $0.6411 on every $100 spent on assets. This is way below average. Sangui Biotech's management efficiency ratios could be used to measure how well Sangui Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Sangui Biotech International has accumulated 48.9 K in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Sangui Biotech Inter has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Sangui Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Sangui Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sangui Biotech Inter sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sangui to invest in growth at high rates of return. When we think about Sangui Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

MAAA FSAEvolent Health
50
Michael GoodwinBURLINGTON STORES
N/A
Norman FerberRoss Stores
74
Dan McCarthyEvolent Health
N/A
Jonathan JDEvolent Health
55
Adam OrvosRoss Stores
58
Michael KobayashiRoss Stores
59
Kali BeyahEvolent Health
N/A
Michael BalmuthRoss Stores
72
Barbara RentlerRoss Stores
66
Ken CaruanaRoss Stores
N/A
Jessica SomersEvolent Health
N/A
Ken JewRoss Stores
N/A
Aammaad ShamsEvolent Health
39
Michael HartshornRoss Stores
55
Brian MorrowRoss Stores
63
Seth FrankEvolent Health
N/A
Connie KaoRoss Stores
N/A
Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. Sangui Biotech International, Inc. was incorporated in 1995 and is based in Witten, Germany. Sangui Biotech is traded on Stock Exchange in Germany. Sangui Biotech International (SBH) is traded on Hamburg Exchange in Germany and employs 1 people.

Management Performance

Return On Asset-0.64

Sangui Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sangui Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-0.64
Profit Margin(1.27) %
Operating Margin(1.50) %
Current Valuation1.6 M
Shares Outstanding209.9 M
Shares Owned By Insiders13.03 %
Price To Earning(12.33) X
Price To Book57.49 X
Price To Sales22.90 X
Revenue69.19 K

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Sangui Biotech Inter using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Other Information on Investing in Sangui Stock

Sangui Biotech financial ratios help investors to determine whether Sangui Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sangui with respect to the benefits of owning Sangui Biotech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY